Six month report January - June 2002:

Six month report January - June 2002: · Group revenues increased 9%, good organic growth in all business areas · Operating earnings, EBITDA, up 5% (up 87% incl. nonrecurring 2001) · Operating cash flow strong at MSEK 480 (-730) MSEK Q2 Curr January-June Curr ency ency (excl nonrecurring 2002 2001 Cha adju 2002 2001 Chang adju items) nge sted e sted Revenues 7,053 6,619 +7% +10% 13,962 12,799 +9% +9% EBITDA1) 1,126 1,076 +5% +7% 2,232 2,122 +5% +4% EBITDA margin 16.0% 16.3% 16.0% 16.6% EBITDA margin (incl 16.0% 2.2% 16.0% 9.3% nonrecurring) Operating cash flow 336 -300 480 -730 Earnings per share, 0.13 0.13 0.39 0.45 SEK Cash earnings2) per 2.21 2.12 4.56 4.26 share, SEK 1) Earnings before depreciation and amortization 2) Net income plus depreciation and amortization Second quarter highlights: · Strong revenue growth, +10% currency adjusted, in all significant respects organic. - Gambro Healthcare revenue per treatment in the US improved by USD 6 to USD 252. · Continued strong development of operating cash flow due to strong growth within all business areas and improved performance within Gambro Healthcare. · Cash flow, currency effects and very few acquisitions led to reduced net debt. · EBITDA margin for the group remained stable from the first quarter this year but somewhat lower than the second quarter last year. - Margin improvement in Gambro Healthcare. Gambro Renal Products' margin was somewhat reduced from last year's high level. Gambro BCT's margin was significantly lower in line with the strategy to widen its business scope, including expansion of PET spending. "We see the momentum in our services business; our action program has started to pay off in a market without external positive contribution", said Sören Mellstig, Gambro president and CEO. "The product and business shift in our product business areas affected our margins in the quarter." For further information please contact: Lars Granlöf, Senior Vice President, CFO, tel. +46-8-613 65 00, +46 70 513 65 48 Janette Jennische, Vice President, Corporate Communications, tel. +46 8 613 65 00, +46 70 212 50 53 Pia Irell, Director, Investor Relations, tel. +46 8 613 65 00, +46 70 513 65 91 Kevin Smith, President, Gambro Inc., Investor Relations US, tel. +1 303 231 4750 Gambro's financial information is also available on the Internet: www.gambro.com The company will host a conference call and web cast to present its second quarter results today at 16:00 Central European time. Teleconference callers should dial +44 (0)20 8781 0577 (if calling from Europe) or +1 303 713 7929 (if calling from the US). Regarding the web cast, please find all related information on Gambro's web site: www.gambro.com/investors/. Next report: Nine-month report:October 25, 2002 ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2002/07/26/20020726BIT00030/wkr0001.doc The full report http://www.waymaker.net/bitonline/2002/07/26/20020726BIT00030/wkr0002.pdf The full report

About Us

Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology. The group, with revenue of approximately SEK 18 billion (USD 2.2 billion), has approximately 17,000 employees in some 40 countries.